The estimated Net Worth of Carol Giltner Gallagher is at least $37.4 Million dollars as of 13 November 2023. Carol Gallagher owns over 270,000 units of Turning Point Therapeutics Inc stock worth over $34,920,362 and over the last 10 years he sold TPTX stock worth over $1,648,802. In addition, he makes $839,556 as Independent Director at Turning Point Therapeutics Inc.
Sign up
Carol Gallagher TPTX stock SEC Form 4 insiders trading
Carol has made over 20 trades of the Turning Point Therapeutics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he bought 270,000 units of TPTX stock worth $67,500 on 13 November 2023.
The largest trade he's ever made was buying 270,000 units of Turning Point Therapeutics Inc stock on 13 November 2023 worth over $67,500. On average, Carol trades about 8,891 units every 69 days since 2014. As of 13 November 2023 he still owns at least 459,418 units of Turning Point Therapeutics Inc stock.
You can see the complete history of Carol Gallagher stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Carol Gallagher biography
Dr. Carol G. Gallagher serves as Independent Director of the Company. She is currently the independent lead director at Atara Bio and Chairperson of Millendo Therapeutics, both public biopharmaceutical companies. Since 2014, Dr. Gallagher has served as a partner with New Enterprise Associates, a venture capital firm. She also currently serves as a director on several private, healthcare company boards. From 2011 until 2018, she was a director at AnaptysBio and she also served as a director of several private boards prior to joining New Enterprise Associates. Dr. Gallagher served as a venture partner with Frazier Healthcare from October 2013 to July 2014. Dr. Gallagher served as President and CEO of Calistoga Pharmaceuticals from September 2008 until April 2011 when the company was acquired by Gilead Sciences. From 2007 to 2008, Dr. Gallagher served as president and CEO of Metastatix, Inc, a biopharmaceutical company. Prior to that time, starting in 1989, she served in various roles at pharmaceutical companies Eli Lilly, Amgen, Agouron Pharmaceuticals, Pfizer, Biogen Idec, CancerVax and Anadys Pharmaceuticals. She studied chemistry at Vanderbilt University and attained her B.S. and Doctor of Pharmacy degrees from the University of Kentucky.
What is the salary of Carol Gallagher?
As the Independent Director of Turning Point Therapeutics Inc, the total compensation of Carol Gallagher at Turning Point Therapeutics Inc is $839,556. There are 5 executives at Turning Point Therapeutics Inc getting paid more, with Yi Larson having the highest compensation of $12,579,400.
How old is Carol Gallagher?
Carol Gallagher is 55, he's been the Independent Director of Turning Point Therapeutics Inc since 2019. There are 5 older and 13 younger executives at Turning Point Therapeutics Inc. The oldest executive at Turning Point Therapeutics Inc is Garry Nicholson, 65, who is the Independent Director.
What's Carol Gallagher's mailing address?
Carol's mailing address filed with the SEC is C/O PMV PHARMACEUTICALS, INC., 1 RESEARCH WAY, PRINCETON, NJ, 08540.
Insiders trading at Turning Point Therapeutics Inc
Over the last 6 years, insiders at Turning Point Therapeutics Inc have traded over $45,947,838 worth of Turning Point Therapeutics Inc stock and bought 2,385,408 units worth $60,168,920 . The most active insiders traders include Plc Gsk, Patrick Machado, and Advisors Llc Orbi Med Capit.... On average, Turning Point Therapeutics Inc executives and independent directors trade stock every 21 days with the average trade being worth of $4,727,594. The most recent stock trade was executed by Paolo Tombesi on 27 July 2022, trading 1,183 units of TPTX stock currently worth $88,654.
What does Turning Point Therapeutics Inc do?
Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company's lead drug candidate, repotrectinib, is a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib, which is being studied in a registrational Phase 2 study in adults and a Phase 1/2 study in pediatric patients, has shown antitumor activity and durable responses among kinase inhibitor treatment-naïve and pre-treated patients. The company's pipeline of drug candidates also includes TPX-0022, targeting MET, CSF1R and SRC, which is being studied in a Phase 1 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in MET; TPX-0046, targeting RET, which is being studied in a Phase 1/2 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in RET; and TPX-0131, a next-generation ALK inhibitor currently pending IND submission. Turning Point's next-generation kinase inhibitors are designed to bind to their targets with greater precision and affinity than existing therapies, with a novel, compact structure that has demonstrated an ability to potentially overcome treatment resistance common with other kinase inhibitors. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment.
What does Turning Point Therapeutics Inc's logo look like?
Complete history of Carol Gallagher stock trades at AnaptysBio Inc, Atara Biotherapeutics Inc, Mirati Therapeutics Inc, Turning Point Therapeutics Inc, Millendo Therapeutics, Pmv Pharmaceuticals Inc, and Certara
Turning Point Therapeutics Inc executives and stock owners
Turning Point Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Yi Larson,
Chief Financial Officer, Executive Vice President -
Mohammad Hirmand,
Executive Vice President, Chief Medical Officer -
Annette North,
Executive Vice President, General Counsel, Secretary -
Dr. Athena Maria Countouriotis M.D.,
Pres, CEO & Director -
Andrew John Partridge,
Exec. VP & Chief Commercial Officer -
Carol Gallagher,
Independent Director -
Dr. Mohammad Hirmand,
Exec. VP & Chief Medical Officer -
Patrick Machado,
Independent Director -
Annette C. North Esq., LLB,
Exec. VP, Gen. Counsel & Company Sec. -
Dr. Siegfried Reich Ph.D.,
Exec. VP & Chief Scientific Officer -
Simeon George,
Independent Director -
Sheila Gujrathi,
Chairman of the Board -
Jacob Chacko,
Independent Director -
Jim Mazzola,
IR Contact Officer -
Garry Nicholson,
Independent Director -
Heather Adams,
Vice President of Human Resources -
Brian Baker,
Vice President - Finance and Administration -
Siegfried Reich,
Executive Vice President, Chief Scientific Officer -
Athena Countouriotis,
President, Chief Executive Officer, Director -
Dr. Jeffrey P. Whitten,
Sr. VP of Pre-Clinical Devel. -
Brian Sun J.D., M.S.,
Sr. VP, Gen. Counsel & Corp. Sec. -
Dr. Gavin Hirst Ph.D.,
Sr. VP of Chemistry & Interim Chief Scientific Officer -
Raymond J. Furey J.D.,
Sr. VP & Chief Compliance Officer -
Dr. Adam D. Levy M.B.A., Ph.D.,
Sr. VP of Investor Relations & Corp. Communications -
Ed Gemo,
Sr. VP & Chief Information Officer -
Kyri K. Van Hoose,
VP of Accounting & Interim Principal Accounting Officer -
Paolo Tombesi,
Exec. VP & CFO -
Jingrong Jean Cui,
Director -
Plc Gsk,
Director -
Hongbo Lu,
Director -
Advisors Llc Orbi Med Capit...,
-
Asset Management, Lp Chen B...,
-
Carl L Gordon,
Director -
Barbara W. Bodem,
Director -
Mark J Alles,
Director -
Paolo Tombesi,
EVP & Chief Financial Officer -
Brian Sun,
SVP & General Counsel -
Steve M Sabus,
SVP & Chief Commercial Officer